Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tenaya Therapeutics ( (TNYA) ) has issued an announcement.
On February 6, 2025, Tenaya Therapeutics appointed Tomohiro Higa as the Interim Principal Accounting Officer. Higa, who has been with the company since January 2025, has a rich background in finance roles at several notable biopharmaceutical companies. In a separate decision, the company’s Board of Directors approved a repricing of underwater stock options for CEO Faraz Ali, effective the same day, to better align incentives and retain key leadership without additional equity grants or cash compensation. This repricing reduces the exercise price of Ali’s options to $1.21 per share, significantly lowering it from the previous range of $5.64 to $15.19 per share.
More about Tenaya Therapeutics
Tenaya Therapeutics operates in the biopharmaceutical industry, focusing on developing therapies for heart disease.
YTD Price Performance: -29.58%
Average Trading Volume: 4,509,668
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $79.22M
See more insights into TNYA stock on TipRanks’ Stock Analysis page.